JPH02504034A - 腫瘍転移の免疫療法のためのウイルス修飾腫瘍ワクチン - Google Patents

腫瘍転移の免疫療法のためのウイルス修飾腫瘍ワクチン

Info

Publication number
JPH02504034A
JPH02504034A JP1502563A JP50256389A JPH02504034A JP H02504034 A JPH02504034 A JP H02504034A JP 1502563 A JP1502563 A JP 1502563A JP 50256389 A JP50256389 A JP 50256389A JP H02504034 A JPH02504034 A JP H02504034A
Authority
JP
Japan
Prior art keywords
tumor
virus
vaccine
cells
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1502563A
Other languages
English (en)
Japanese (ja)
Inventor
シルマツヘル，フオルケル
Original Assignee
シルマッヘル，フォルケル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6348527&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH02504034(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by シルマッヘル，フォルケル filed Critical シルマッヘル，フォルケル
Publication of JPH02504034A publication Critical patent/JPH02504034A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP1502563A 1988-03-01 1989-02-27 腫瘍転移の免疫療法のためのウイルス修飾腫瘍ワクチン Pending JPH02504034A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3806565A DE3806565A1 (de) 1988-03-01 1988-03-01 Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
DE3806565.7 1988-03-01

Publications (1)

Publication Number Publication Date
JPH02504034A true JPH02504034A (ja) 1990-11-22

Family

ID=6348527

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1502563A Pending JPH02504034A (ja) 1988-03-01 1989-02-27 腫瘍転移の免疫療法のためのウイルス修飾腫瘍ワクチン

Country Status (10)

Country Link
US (1) US5273745A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0331102B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH02504034A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR900700130A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE90877T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU3188989A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE3806565A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK541889D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2042828T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1989007946A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9144603B2 (en) 2008-09-12 2015-09-29 Mie University Cell capable of expressing exogenous GITR ligand

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3922444A1 (de) * 1988-03-01 1991-01-10 Deutsches Krebsforsch Virusmodifizierte tumorvakzine fuer die immuntherapie von tumormetastasen
DE4204132C2 (de) * 1991-02-12 1997-12-18 Rudolf Dr Pekar Aufbereitung für die Gewinnung von Vakzinen für eine Immuntherapie
DE69232890T2 (de) * 1991-10-04 2003-10-09 The Johns Hopkins University School Of Medicine, Baltimore Regulierung der systemischen immunantworten mittels zytokinen und antigenen
ATE411809T1 (de) * 1993-04-30 2008-11-15 Wellstat Biologics Corp Zusuammensetzungen zur behandlung von krebs mittels viren
DE19506483A1 (de) * 1995-02-24 1996-08-29 Jens Dr Dr Atzpodien Lyophilisat-Vakzine
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
EP0805207A1 (en) * 1996-05-02 1997-11-05 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression plasmid for tumor rejection
ATE245163T1 (de) * 1996-05-03 2003-08-15 Univ Jefferson Impfstoff gegen metastasierenden kolorektalkrebs.
CA2242590A1 (en) * 1996-10-04 1998-04-09 Thomas Jefferson University T cells mediating an immune response and methods of use
DE69731950T2 (de) * 1997-08-22 2005-05-19 Science Park Raf S.P.A. Tumorvakzinierung mittels Verwendung autologer oder HLA-verwandter Antigen präsentierender Zellen (APC), die mit einem Tumorantigen sowie einem eine Immunantwort hervorrufenden Fremdantigen transduziert sind
TW575420B (en) * 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
WO2000062735A2 (en) * 1999-04-15 2000-10-26 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
EP1092439A1 (en) * 1999-10-13 2001-04-18 Thorsten Dr. Ahlert Activation of antigen-specific T cells by virus/antigen-treated dendritic cells
RU2172182C1 (ru) * 2000-07-27 2001-08-20 Бритов Василий Александрович Способ профилактики и лечения заболеваний иммунной системы и средство для его осуществления
KR20040094635A (ko) * 2003-05-02 2004-11-10 주식회사 엠디바이오알파 항종양 활성의 유도를 위한 종양 백신의 제조방법 및그것을 함유하고 있는 약제 조성물
ES2668464T3 (es) 2005-12-02 2018-05-18 Icahn School Of Medicine At Mount Sinai Virus quiméricos de la enfermedad de Newcastle que presentan proteínas de superficie no naturales y sus usos
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
US20110206736A1 (en) * 2008-09-23 2011-08-25 Thomas Jefferson University Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same
EP2327764B1 (en) * 2009-11-30 2011-12-28 United Cancer Research Institute New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
SG10201802982WA (en) 2013-03-14 2018-06-28 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
CA2940570A1 (en) 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
US12391957B2 (en) 2018-08-17 2025-08-19 Icahn School Of Medicine At Mount Sinai Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2918927A1 (de) * 1979-05-10 1980-11-20 Hans Prof Dr Limburg Arzneipraeparat zur behandlung von carcinomen und verfahren zu dessen herstellung
DE3432714A1 (de) * 1984-09-06 1986-04-24 Behringwerke Ag, 3550 Marburg Tumortherapeutikum und verfahren zu seiner herstellung
HU197517B (en) * 1984-07-30 1989-04-28 Laszlo Csatary Process for production of terapeutical composition applicable against virus infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLINICAL AND EXPERIMENTAL METASTASIS=1987 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9144603B2 (en) 2008-09-12 2015-09-29 Mie University Cell capable of expressing exogenous GITR ligand

Also Published As

Publication number Publication date
DE58904760D1 (de) 1993-07-29
EP0331102A1 (de) 1989-09-06
EP0331102B1 (de) 1993-06-23
KR900700130A (ko) 1990-08-11
AU3188989A (en) 1989-09-22
DK541889A (da) 1989-10-31
ES2042828T3 (es) 1993-12-16
DK541889D0 (da) 1989-10-31
US5273745A (en) 1993-12-28
DE3806565A1 (de) 1989-09-14
ATE90877T1 (de) 1993-07-15
DE3806565C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1991-04-25
WO1989007946A1 (en) 1989-09-08

Similar Documents

Publication Publication Date Title
JPH02504034A (ja) 腫瘍転移の免疫療法のためのウイルス修飾腫瘍ワクチン
US4108983A (en) Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors
Dupont et al. Studies of immunity in typhoid fever: protection induced by killed oral antigens or by primary infection
Scott Potentiation of the tumor-specific immune response by Corynebacterium parvum
AU2009242471B2 (en) Vaccine compositions and methods
US11833173B2 (en) Th1 vaccination priming for active immunotherapy
JP6796146B2 (ja) 水酸化アルミニウムゲル−塩化ナトリウム複合免疫学的アジュバント、並びにその調製方法及びその使用
JPH09511737A (ja) 免疫治療剤とその使用
Fujiwara et al. The augmentation of tumor‐specific immunity by virus help. I. Demonstration of vaccinia virus‐reactive helper T cell activity involved in enhanced induction of cytotoxic T lymphocyte and antibody responses
US6726913B1 (en) Treatment of dermal tumors, warts, and viral infections of the respiratory tract in humans using heat-killed P. acnes
EP1220688A1 (en) Treatment of dermal tumors, warts, and viral infections using heat-killed p. acnes
CN102266551B (zh) 可用于治疗人或动物免疫相关性疾病的白介素-4治疗性疫苗
RU2122862C1 (ru) Бесклеточная антистафилококковая вакцина для лечения хронической стафилококковой инфекции
EP1272216B1 (en) A vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias
US4711876A (en) Process for the treatment and remission of AIDS (acquired immune deficiency syndrome)
WO2004096244A1 (en) Method of preparing tumor vaccine for the inducement of anti-tumor activity and a pharmaceutical composition containing the same
Marx Tumor immunology (II): Strategies for cancer therapy
Pomer et al. Sequential treatment of patients with advanced renal cell carcinoma with autologous tumor vaccine and subcutaneous administration of recombinant interleukin-2 and interferon α2b
Hobohm Healing Heat-an essay on cancer fever therapy: Immunological basics and practical application with 16 case reports
Maugh et al. Immunotherapy: New Strategies for Cancer Therapy
Hofman et al. immunological preparations
Castro Approaches to the Immunological Treatment of Tumours
HK1158499B (en) Th1 vaccination priming for active immunotheraphy
HK1158499A (en) Th1 vaccination priming for active immunotheraphy
GB2428006A (en) AMI-3 vaccine comprising group A Streptococcus pyogenes bacteria